Adage Capital Partners’s C4 Therapeutics CCCC Stock Holding History

Adage Capital Partners’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.52M	Buy	+325,000	New	+$1.11M	﹤0.01%	886
2025 Q3	–	Sell	-200,000	Closed	-$286K	–	899
2025 Q2	$286K	Sell	200,000 -1,350,000	-87%	-$1.96M	﹤0.01%	822
2025 Q1	$2.48M	Hold	1,550,000	–	–	﹤0.01%	752
2024 Q4	$5.58M	Buy	1,550,000 +1,030,000	+198%	+$5.12M	0.01%	706
2024 Q3	$2.96M	Buy	+520,000	New	+$3.13M	0.01%	758
2022 Q1	–	Sell	-996,477	Closed	-$32.1M	–	1087
2021 Q4	$32.1M	Buy	996,477 +185,000	+23%	+$7.32M	0.06%	331
2021 Q3	$36.3M	Buy	811,477 +121,477	+18%	+$5.2M	0.07%	278
2021 Q2	$26.1M	Sell	690,000 -190,498	-22%	-$6.82M	0.05%	374
2021 Q1	$32.6M	Sell	880,498 -10,000	-1%	-$398K	0.07%	313
2020 Q4	$29.5M	Buy	+890,498	New	+$25.8M	0.06%	318

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Adage Capital Partners's CCCC Position: Q2 2026 in Review

Adage Capital Partners opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 325,000 shares worth $1.52M. The stake represents ﹤0.01% of the portfolio and ranks #886 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in CCCC as recently as Q2 2025.

Adage Capital Partners first reported a position in CCCC in Q4 2020 and has held it in 10 quarters since. The position peaked at $36.3M in Q3 2021. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Adage Capital Partners held 325,000 shares of C4 Therapeutics worth $1.52M as of Q2 2026.
C4 Therapeutics was a new Adage Capital Partners position in Q2 2026.
C4 Therapeutics made up ﹤0.01% of Adage Capital Partners's portfolio in Q2 2026, its #886 holding.
Adage Capital Partners first reported a position in C4 Therapeutics in Q4 2020 and has held it in 10 quarters since.
Adage Capital Partners's C4 Therapeutics position peaked at $36.3M in Q3 2021.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.